Paper33517606
Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact.
Yip TC and 2 others. Clin Mol Hepatol, 2021. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact. Papers, record 33517606. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33517606
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Negligible risk of hepatocellular carcinoma in chronic hepatitis B patients in immune-tolerant phase: Myth or fact.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Hepatitis B, Chronic | Major topic |
| Liver Neoplasms | Major topic |
| Biomarkers | |
| Hepatitis B e Antigens | |
| Hepatitis B virus | |
| Humans |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment on | 33317247 | Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. | https://conductscience.org/library/papers/33317247 |
Source PubMed
References16
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 26563120 | Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. | Hepatol Int | 2016 | https://conductscience.org/library/papers/26563120 | PubMed |
| 2 | 29353469 | Management of chronic hepatitis B patients in immunetolerant phase: what latest guidelines recommend. | Clin Mol Hepatol | 2018 | https://conductscience.org/library/papers/29353469 | PubMed |
| 3 | 31185710 | KASL clinical practice guidelines for management of chronic hepatitis B. | Clin Mol Hepatol | 2019 | https://conductscience.org/library/papers/31185710 | PubMed |
| 4 | 33288393 | Negligible HCC risk during stringently defined untreated immune-tolerant phase of chronic hepatitis B. | Eur J Intern Med | 2021 | https://conductscience.org/library/papers/33288393 | PubMed |
| 5 | 27084039 | Adaptive immunity in HBV infection. | J Hepatol | 2016 | https://conductscience.org/library/papers/27084039 | PubMed |
| 6 | 31025388 | Improvement in enhanced liver fibrosis score and liver stiffness measurement reflects lower risk of hepatocellular carcinoma. | Aliment Pharmacol Ther | 2019 | https://conductscience.org/library/papers/31025388 | PubMed |
| 7 | 23415803 | Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. | Gastroenterology | 2013 | https://conductscience.org/library/papers/23415803 | PubMed |
| 8 | 32621944 | Repeated FIB-4 measurements can help identify individuals at risk of severe liver disease. | J Hepatol | 2020 | https://conductscience.org/library/papers/32621944 | PubMed |
| 9 | 24462735 | Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA. | Gastroenterology | 2014 | https://conductscience.org/library/papers/24462735 | PubMed |
| 10 | 29405329 | Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. | Hepatology | 2018 | https://conductscience.org/library/papers/29405329 | PubMed |
| 11 | 28427875 | EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. | J Hepatol | 2017 | https://conductscience.org/library/papers/28427875 | PubMed |
| 12 | 29758335 | Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B. | J Hepatol | 2018 | https://conductscience.org/library/papers/29758335 | PubMed |
| 13 | 30754963 | Unmet need in chronic hepatitis B management. | Clin Mol Hepatol | 2019 | https://conductscience.org/library/papers/30754963 | PubMed |
| 14 | 33317247 | Negligible risks of hepatocellular carcinoma during biomarker-defined immune-tolerant phase for patients with chronic hepatitis B. | Clin Mol Hepatol | 2021 | https://conductscience.org/library/papers/33317247 | PubMed |
| 15 | 29055908 | High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. | Gut | 2018 | https://conductscience.org/library/papers/29055908 | PubMed |
| 16 | 29029102 | Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study. | J Infect Dis | 2017 | https://conductscience.org/library/papers/29029102 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41899088 | Heterogeneity Analysis of HBeAg-Positive Chronic Hepatitis B Patients with Ultra-High Viral Load (HBV DNA ≥ 7.0 log10 IU/mL). | J Clin Med | 2026 | https://conductscience.org/library/papers/41899088 | PubMed |
| 39979574 | Projected Mitigation of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B in the Gray Zone and the Immune-Tolerant Phase in the United States. | Dig Dis Sci | 2025 | https://conductscience.org/library/papers/39979574 | PubMed |
| 37196991 | Treated chronic hepatitis B is a good prognostic factor of diffuse large B-cell lymphoma. | Clin Mol Hepatol | 2023 | https://conductscience.org/library/papers/37196991 | PubMed |
| 36603573 | Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase. | Clin Mol Hepatol | 2023 | https://conductscience.org/library/papers/36603573 | PubMed |
| 34298640 | Association of Physical Activity with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34298640 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/33517606
GET https://conductscience.org/api/papers/v1/33517606/authors